| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
H.A. NASRALLAH,
L.E. DELISI
|
iii
|
|
|
|
Introduction
|
Lynn E. DeLisi
|
v
|
|
| Oral Presentations |
| |
Article Title |
Author(s) |
Pages |
|
|
|
LABORATORY STUDIES OF DELTA-9-THC IN HUMANS: RELEVANCE TO SCHIZOPHRENIA
|
Deepak Cyril D'Souza,
Daniel Mathalon,
Edward Perry
|
1
|
|
|
|
GENETIC MODERATION OF THE CANNABIS INDUCED PSYCHOSIS
|
Cécile Henquet,
Jim van Os
|
1
|
|
|
|
CANNABIS-INDUCED PSYCHOSIS AS A MODEL OF SCHIZOPHRENIA?
|
Robin M. Murray
|
2
|
|
|
|
A FUNCTIONAL MRI STUDY OF THE EFFECTS OF DELTA-9-THC AND CANNABIDIOL EFFECTS IN HUMANS
|
Philip McGuire
|
2
|
|
|
|
CANNABIS USE AND RISK OF SCHIZOPHRENIA: POTENTIAL BIOLOGICAL MECHANISMS
|
David A. Lewis
|
2
|
|
|
|
REACTION TO EMOTIONAL FACES DURING ADOLESCENCE IS INFLUENCED BY SEX STEROID LEVELS IN THE MONKEY
|
Cyndi Shannon Weickert,
Debora Rothmond,
Sarah Ward,
A. Brent Richards,
Pam Noble,
Ruth Woodward,
Jim Winslow
et al.
|
2-3
|
|
|
|
FACIAL EMOTION IDENTIFICATION AND EXPRESSION IN SCHIZOPHRENIA: LESSONS FROM IMAGE ANALYSIS OF BRAINS AND FACES
|
Raquel E. Gur
|
3
|
|
|
|
ARE VISUO-COGNITIVE DEFICITS A VULNERABILITY MARKER FOR SCHIZOPHRENIA? EVIDENCE FROM PATIENTS AND FIRST-DEGREE RELATIVES
|
Carmel Loughland
|
3
|
|
|
|
SCAN PATH DATA ON HEALTHY TWINS AND PATIENTS: ARE SPATIAL FACTORS A GENETIC MARKER FOR SCHIZOPHRENIA?
|
Patricia Bestelmeyer
|
3
|
|
|
|
REMEDIATION OF FACIAL EMOTION PROCESSING DEFICITS IN SCHIZOPHRENIA
|
Melissa Green
|
4
|
|
|
|
THE HETEROGENEITY OF ANTIPSYCHOTIC DRUG RESPONSE AND PREDICTION OF OUTCOME, ARE WE FURTHER AHEAD? - AN OVERVIEW
|
A. George Awad
|
4
|
|
|
|
NEUROCOGNITIVE TASK PERFORMANCE AS AN OUTCOME MEASURE IN ANTIPSYCHOTIC TREATMENT TRIALS
|
Richard Keefe
|
4
|
|
|
|
GREATER CORTICAL THICKNESS IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA WHO ARE RESPONSIVE TO ATYPICAL ANTIPSYCHOTICS
|
Philip R. Szeszko,
Catherine L. Narr,
Owen R. Phillips,
Joanne McCormack,
Serge Sevy,
John M. Kane,
Robert M. Bilder,
Delbert Robinson
et al.
|
5
|
|
|
|
EFFECTS OF ANTIPSYCHOTIC DRUGS ON REGIONAL NEURONAL ACTIVITY AND ACTIVATION: ASL, VASO, AND fMRI BOLD
|
Carol A. Tamminga,
Binu Thomas,
Jinsoo Uh,
Hanzhang Lu
|
5
|
|
|
|
PHARMACOGENETIC APPROACHES TO ANTIPSYCHOTIC DRUG RESPONSE HETEROGENEITY
|
Anil K. Malhotra
|
5
|
|
|
|
MOLECULAR MARKERS OF CORTICAL GABA NEUROTRANSMISSION IN SCHIZOPHRENIA: REGIONAL AND CELLULAR PHENOTYPES
|
David A. Lewis,
Takanori Hashimoto
|
6
|
|
|
|
NEURAL SYNCHRONY DURING PERCEPTUAL ORGANISATION IN SCHIZOPHRENIA: EEG AND MEG-STUDIES
|
Peter Uhlhaas
|
6
|
|
|
|
IMPAIRED LOW AND HIGH-FREQUENCY OSCILLATORY ACTIVITY DURINGWORKING MEMORY IN ADOLESCENTS WITH SCHIZOPHRENIA
|
Corinna Haenschel
|
6
|
|
|
|
MODELING GABA ALTERATIONS IN SCHIZOPHRENIA: A LINK BETWEEN IMPAIRED INHIBITION AND ALTERED GAMMA AND BETA RANGE AUDITORY ENTRAINMENT
|
Dorea Vierling-Claassen,
Peter Siekmeier,
Steven Stufflebeam,
Nancy Kopell
|
7
|
|
|
|
GLUTAMATE IS SENSATIONAL. THINK ABOUT IT!
|
Daniel Javitt
|
7
|
|
|
|
STRATEGIES TO ENHANCE NMDA NEUROTRANSMISSION IN SCHIZOPHRENIA
|
Guochuan Tsai
|
7-8
|
|
|
|
MOLECULAR STUDIES OF NMDA RECEPTOR MODULATORS IN SCHIZOPHRENIA
|
Paul Harrison,
L. Verrall,
P.W.J. Burnet
|
8
|
|
|
|
D-SERINE VS. PLACEBO IN THE TREATMENT OF NEGATIVE SYMPTOMS AND COGNITIVE IMPAIRMENT OF SCHIZOPHRENIA
|
Mark Weiser,
D.C. Javitt,
U. Heresco-Levy,
A. Abramovitch,
A. Teitlebaum,
A. Doron,
M. Davidson
et al.
|
8
|
|
|
|
THE BUSINESS OF SCIENCE AS IT APPLIES TO SCHIZOPHRENIA DRUG DEVELOPMENT
|
Gary Pisano
|
8
|
|
|
|
REWARDS AND CHALLENGES IN SCHIZOPHRENIA DRUG DEVELOPMENT
|
Anders Gersel Pedersen
|
8
|
|
|
|
INCREASING PLACEBO RESPONSE IN ANTI-PSYCHOTIC TRIALS: FACT OR MYTH
|
Anand Ravi
|
8
|
|
|
|
WHAT ARE THE RULES? COULD WE HAVE AVOIDED UNPLEASANT SURPRISES?
|
Susanna Del Signore
|
8
|
|
|
|
IS COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA A REALISTIC TARGET FOR PHARMACOLOGICAL INTERVENTION?
|
Michael Davidson
|
8-9
|
|
|
|
ALTERED FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA: A SMALL WORLD NETWORK ANALYSIS OF RESTING fMRI
|
Kelvin Lim,
Bryon Mueller,
Jazmin Camchong,
Chris Bell
|
9
|
|
|
|
INVESTIGATING THE NEURAL BASIS OF SENSORY PREDICTION DEFICITS IN SCHIZOPHRENIA USING fMRI
|
Sukhi Shergill,
Dan Joyce,
Paul Bays,
Daniel Wolpert,
Chris Frith
et al.
|
9
|
|
|
|
DISRUPTION OF WHITE MATTER INTEGRITY IN THE INFERIOR LONGITUDINAL FASCICULUS IN ADOLESCENTS WITH SCHIZOPHRENIA AS REVEALED BY FIBER TRACTOGRAPHY
|
Sanjiv Kumra
|
10
|
|
|
|
FIBER-BASED ANALYSIS OF DIFFUSION TENSOR IMAGING AND MAGNETIZATION TRANSFER RATIO SCANS IN SCHIZOPHRENIA
|
Rene Mandl,
Hugo Schnack,
Martijn van den Heuvel,
Rehana de Vries,
Judy Luigjes,
Wiepke Cahn,
René Kahn,
Hilleke Hulshoff Pol
et al.
|
10
|
|
|
|
EXPLORING THE NEURAL SUBSTRATE OF THE VULNERABILITY TO FIRST EPISODE PSYCHOSIS USING fMRI
|
Marco Picchioni,
Mathew Broome,
Sara Weinstein,
Pall Matthiason,
Philip McGuire
et al.
|
10
|
|
|
|
WHERE DO AUDITORY HALLUCINATIONS COME FROM? RIGHT SUPERIOR TEMPORAL SULCUS AND SPATIAL LOCATION OF AUDITORY HALLUCINATIONS
|
Marion Plaze,
Marie-Laure Paillère-Martinot,
Jani Penttilä,
Dominique Januel,
Renaud de Beaurepair,
Franck Bellivier,
Jamila Andoh,
André Galinowski,
Eric Artiges,
Jean-Pierre Olié,
Jean-François Mangin,
Jean-Luc Martinot,
Pamela Butler
et al.
|
10-11
|
|
|
|
ASTROCYTES IN THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA: REGULATION OF GLUTAMATE AND GABA
|
Daniel Kondziella
|
11
|
|
|
|
ASTROCYTES IN THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA: ABNORMAL EXPRESSION OF EXTRACELLULAR MATRIX MOLECULES
|
Sabina Berretta
|
11
|
|
|
|
INTEGRATINGMOLECULAR AND CELLULAR DEFICITS IN SCHIZOPHRENIA
|
Joseph Buxbaum
|
11-12
|
|
|
|
MICROGLIA IN SCHIZOPHRENIA
|
Steven E. Arnold
|
12
|
|
|
|
PERCEPTUAL ORGANIZATION OF SIMILARITY AND PROXIMITY IS IMPAIRED IN SCHIZOPHRENIA
|
Pamela Butler,
Roey Pasternak,
Daniel Javitt,
Daniel Kurylo
|
12
|
|
|
|
ABNORMAL INHIBITORY CONTROL OF VISUALMOTION PROCESSING IN SCHIZOPHRENIA
|
Yue Chen,
Dan Norton,
Dost Ongur
|
12
|
|
|
|
TARGET DETECTION DISCRIMINATION INVESTIGATED BY EVENT RELATED FUNCTIONAL MAGNETIC RESONANCE IMAGING
|
Raquel E. Gur
|
13
|
|
|
|
ANTISACCADE DEFICITS IN SUBJECTS EITHER GENETICALLY OR CLINICALLY AT RISK FOR SCHIZOPHRENIA
|
Michael Wagner,
Nadine Petrovsky,
Juergen Brinkmeyer,
Wolfgang Wölwer,
Andreas Bechdolf,
Stefan Ruhrmann,
Joachim Klosterkötter,
Wolfgang Maier,
Ingo Frommann
et al.
|
13
|
|
|
|
RIGHT PARIETAL CORTEX, THE NEGLECT SYNDROME AND SCHIZOPHRENIA
|
James Danckert
|
13
|
|
|
|
INTERACTION OF VISUAL ATTENTIONAL NETWORKS: CLINICAL AND THERAPEUTICAL IMPLICATIONS FOR COGNITIVE REMEDIATION IN STABILIZED PATIENTS
|
Isabelle Amado
|
13
|
|
|
|
GENOMIC FINDINGS IN SCHIZOPHRENIA, ANIMAL MODELS AND INTERMEDIATE PHENOTYPES
|
D. Rujescu,
I. Giegling,
A. Hartmann,
J. Genius,
C. Mulert,
U. Hegerl,
A. Ruppert,
H. Grunze,
C. Francks,
C. Francks,
H.J. Möller
et al.
|
14
|
|
|
|
PERI-PUBERTAL MATURATION AFTER DEVELOPMENTAL DISTURBANCE: A MODEL FOR PSYCHOSIS ONSET IN THE RAT
|
Gwenaëlle Le Pen,
Franck Hazane,
Raphaël Gourevitch,
Thérèse-Marie Jay,
Marie-Odile Krebs
et al.
|
14
|
|
|
|
DEVELOPMENTAL REGULATION OF PREFRONTAL CORTEX PLASTICITY DURING THE PERI-ADOLESCENT TRANSITION TO ADULTHOOD: IMPLICATIONS FOR SCHIZOPHRENIA PATHOPHYSIOLOGY
|
Kuei-Yuan Tseng
|
14-15
|
|
|
|
NEUROBEHAVIORAL AND IMMUNOLOGICAL CONSEQUENCES OF PRENATAL IMMUNE ACTIVATION IN RATS
|
Jose Borrell
|
15
|
|
|
|
BRAIN GLUTATHIONE CONCENTRATION IN FIRST-EPISODE PSYCHOSIS: A MAGNETIC RESONANCE SPECTROSCOPY STUDY
|
Stephen Wood
|
15
|
|
|
|
CHANGES IN CORTICAL THICKNESS IN PATIENTS WITH SCHIZOPHRENIA: A 5-YEAR LONGITUDINALMRI STUDY ACROSS THE COURSE OF ILLNESS
|
Neeltje van Haren,
Hugo Schnack,
Hilleke Hulshoff Pol,
Martin Cahn van den Heuvel,
Wiepke Cahn,
Claude Le Page,
Alana Evans,
René Kahn
et al.
|
15-16
|
|
|
|
ASSOCIATION OF FIBROBLAST GROWTH FACTOR 2 (FGF2) WITH HIPPOCAMPAL VOLUME IN DUTCH SCHIZOPHRENIA PATIENTS
|
Steven Bakker,
Neeltje van Haren,
Mechteld Hoogendoorn,
Cedric Koolschijn,
Hilleke Hulshoff Pol,
Richard Sinke,
Roel Ophoff,
René Kahn
et al.
|
16
|
|
|
|
CORTICAL FOLDING IN EARLY-ONSET SCHIZOPHRENIA
|
Jani Penttilä,
Arnaud Cachia,
Marie-Laure Paillère-Martinot,
Jean-François Mangin,
Lisa Burke,
Richard Corrigall,
Sophia Frangou,
Jean-Luc Martinot
et al.
|
16
|
|
|
|
DISEASE SPECIFIC ALTERATION OF ORBITOFRONTAL SULCOGYRAL PATTERN IN FIRST EPISODE SCHIZOPHRENIA
|
Motoaki Nakamura,
Dean Salisbury,
Yoshio Hirayasu,
Robert Mc Carley,
Martha Shenton
et al.
|
16-17
|
|
|
|
LEARNING POTENTIAL IN SCHIZOPHRENIA IS RELATED TO NEURONAL INTEGRITY OF THE ANTERIOR CINGULATE CORTEX AS MEASURED BY PROTON MAGNETIC RESONANCE SPECTROSCOPY
|
Patricia Ohrmann,
Jochen Bauer,
Harald Kugel,
Ansgar Siegmund,
Thomas Suslow,
Karl Wiedl,
Matthias Rothermundt,
Volker Arolt,
Anya Pedersen
et al.
|
17
|
|
|
|
ADOLESCENTS WITH 22q11.2 DELETION SYNDROME: A POPULATION ULTRA HIGH-RISK FOR SCHIZOPHRENIA
|
Martin Debbane,
Martial Van der Linden,
Marie Schaer,
Bronwyn Glaser,
Stephan Eliez
et al.
|
17
|
|
|
|
CARDIOVASCULAROUTCOME AND SCHIZOPHRENIA IN SWEDEN
|
Urban Ösby
|
18
|
|
|
|
THE EMERGING FIELD OF METABOLOMICS: POTENTIAL BIOMARKERS OF TREATMENT RESPONSE IN SCHIZOPHRENIA
|
Rima Kaddurah-Dauok
|
18
|
|
|
|
PSYCHIATRIC DIAGNOSIS AS AN RISK FACTOR FOR METABOLIC DISTURBANCES. RESULTS FROM A COMPREHENSIVE, NATURALISTIC SCREENING PROGRAM
|
Ruud Van Winkel,
Jim van Os,
Ivan Celic,
Martien Wampers,
Jos Peuskens,
Marc De Hert
et al.
|
18
|
|
